Opiant Pharmaceuticals, Inc.

Complete the New Drug Application submission for OPNT003 in opioid overdose

Deadline passed; outcome being checked

Announced: 4 Mar 2021
Due: 31 Dec 2021
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“The Company remains on track to complete its New Drug Application ("NDA") submission for use of OPNT003 in opioid overdose by end 2021”

SourceOpiant Pharmaceuticals, Inc. Form 8-K press release, 2021-03-04
FilingSEC filing index
Deadline as statedby end 2021
Deadline used31 Dec 2021, the last day of the stated period
TypeRegulatory
Permanent referenceKI-C-2021-C385508-025179
Cite as https://keptindex.org/c/KI-C-2021-C385508-025179/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Regulatory other
Indicative materiality: Medium rules
Action: Complete
Deliverable: NDA submission for OPNT003 in opioid overdose
Language: Firm (“will”, “on track to”)
In the company’s control: High
Specificity: High

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Opiant Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-C385508-025179 · Corrections policy